Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro

• Main Authors: Omar S. Qureshi (Author), Emma J. Sutton (Author), Rosemary F. Bithell (Author), Shauna M. West (Author), Rona M. Cutler (Author), Gillian McCluskey (Author), Graham Craggs (Author), Asher Maroof (Author), Nicholas M. Barnes (Author), David P. Humphreys (Author), Stephen Rapecki (Author), Bryan J. Smith (Author), Anthony Shock (Author)
• Formato: Livro
• Publicado em: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

ABSTRACTRozanolixizumab is a humanized anti-neonatal Fc receptor (FcRn) monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4) sub-class, currently in clinical development for the treatment of IgG autoantibody-driven diseases. This format is frequently used for therapeutic mAbs due to its intrins...